NASDAQ:MREO Mereo BioPharma Group (MREO) Stock Price, News & Analysis $0.32 -0.03 (-7.69%) As of 02:32 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Mereo BioPharma Group Stock (NASDAQ:MREO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mereo BioPharma Group alerts:Sign Up Key Stats Today's Range$0.32▼$0.3650-Day Range$0.24▼$0.4052-Week Range$0.20▼$2.37Volume1.01 million shsAverage Volume5.26 million shsMarket Capitalization$51.58 millionP/E RatioN/ADividend YieldN/APrice Target$1.67Consensus RatingHold Company Overview Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing medicines for rare diseases and other serious conditions with limited treatment options. The company’s activities include drug discovery, clinical development and commercialization through partnerships with larger pharmaceutical companies. Mereo’s pipeline has included setrusumab, an investigational anti-sclerostin antibody being developed for osteogenesis imperfecta, a rare genetic disorder characterized by fragile bones. The company has also developed alvelestat, an oral neutrophil elastase inhibitor being evaluated for diseases associated with excessive neutrophilic inflammation, including severe alpha-1 antitrypsin deficiency-associated lung disease and bronchiectasis. Founded in 2015, Mereo is headquartered in London and conducts development activities through international clinical and commercial collaborations. Its shares trade on the Nasdaq Capital Market under the symbol MREO.AI Generated. May Contain Errors. Read More Mereo BioPharma Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreMREO MarketRank™: Mereo BioPharma Group scored higher than 74% of companies evaluated by MarketBeat, and ranked 154th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingHold Consensus RatingMereo BioPharma Group has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialMereo BioPharma Group has a consensus price target of $1.67, representing about 420.8% upside from its current price of $0.32.Amount of Analyst CoverageMereo BioPharma Group has only been the subject of 4 research reports in the past 90 days.Read more about Mereo BioPharma Group's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mereo BioPharma Group are expected to grow in the coming year, from ($0.04) to ($0.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mereo BioPharma Group is -8.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mereo BioPharma Group is -8.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMereo BioPharma Group has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Mereo BioPharma Group's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.79% of the float of Mereo BioPharma Group has been sold short.Short Interest Ratio / Days to CoverMereo BioPharma Group has a short interest ratio ("days to cover") of 1.25, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mereo BioPharma Group has recently decreased by 12.92%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMereo BioPharma Group does not currently pay a dividend.Dividend GrowthMereo BioPharma Group does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.05 News SentimentMereo BioPharma Group has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Mereo BioPharma Group this week, compared to 4 articles on an average week.Search Interest4 people have searched for MREO on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Mereo BioPharma Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mereo BioPharma Group insiders have not sold or bought any company stock.Percentage Held by Insiders6.50% of the stock of Mereo BioPharma Group is held by insiders.Percentage Held by Institutions62.83% of the stock of Mereo BioPharma Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mereo BioPharma Group's insider trading history. Receive MREO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MREO Stock News HeadlinesMereo BioPharma Group plc - Sponsored ADR (MREO) - What Are Researchers Thinking About This Stock?October 12 at 2:44 AM | americanbankingnews.comMereo BioPharma Group plc(NasdaqCM:MREO) dropped from S&P Global BMI IndexSeptember 22, 2026 | marketscreener.comMWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 12 at 1:00 AM | Awesomely (Ad)Mereo BioPharma Group PLC ADRSeptember 6, 2026 | barrons.comMereo BioPharma Group plc: Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung ...August 11, 2026 | finanznachrichten.deMereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate HighlightsAugust 11, 2026 | markets.businessinsider.comMereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)August 11, 2026 | markets.businessinsider.comSentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)August 11, 2026 | prnewswire.comSee More Headlines MREO Stock Analysis - Frequently Asked Questions How have MREO shares performed this year? Mereo BioPharma Group's stock was trading at $0.4167 at the beginning of the year. Since then, MREO shares have decreased by 23.2% and is now trading at $0.32. How were Mereo BioPharma Group's earnings last quarter? Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) announced its earnings results on Wednesday, August, 12th. The company reported ($0.01) EPS for the quarter, hitting analysts' consensus estimates of ($0.01). When did Mereo BioPharma Group IPO? Mereo BioPharma Group (MREO) raised $50 million in an initial public offering on Wednesday, April 24th 2019. The company issued 2,838,021 shares at $17.62 per share. How do I buy shares of Mereo BioPharma Group? Shares of MREO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mereo BioPharma Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mereo BioPharma Group investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), Disc Medicine (IRON), Jabil (JBL) and Builders FirstSource (BLDR). Company Calendar Last Earnings8/12/2026Today10/12/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 7 days, MREO's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MREO CIK1719714 Webwww.mereobiopharma.com Phone44-33-3023-7300FaxN/AEmployees39Year Founded2015Price Target and Rating Average Price Target for Mereo BioPharma Group$1.67 High Price Target$3.00 Low Price Target$1.00 Potential Upside/Downside+420.8%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$41.88 million Net MarginsN/A Pretax Margin-7,142.00% Return on Equity-74.82% Return on Assets-64.28% Debt Debt-to-Equity RatioN/A Current Ratio5.88 Quick Ratio5.88 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book1.23Miscellaneous Outstanding Shares159,691,000Free Float149,311,000Market Cap$51.10 million OptionableOptionable Beta0.20 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:MREO) was last updated on 10/12/2026 by MarketBeat.com Staff. From Our PartnersHOST Just Entered the AI Data Center Race in a BIG WayHost Digital Inc. (NYSE American: HOST) completed its merger with Healthy Choice Wellness Corp. on September 1...Trading Wire | SponsoredThe AI Infrastructure Play Kevin O'Leary Is BackingKevin O'Leary became a strategic investor in a NASDAQ-listed AI infrastructure company, calling it essentially...The Tomorrow Investor | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredFox News: Wall Street Can Seize Your RetirementFox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | SponsoredUrgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20thMarc Chaikin, a 60-year Wall Street veteran whose past clients include George Soros and Steve Cohen, built a s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Mereo BioPharma Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MREO Stock Alerts